Get started

Stockstobuy

wave III of 3 in CARYSIL...upside potential of 25%Carysil Limited, together with its subsidiaries, manufactures and trades in quartz kitchen and stainless steel kitchen sinks, bath products, tiles, kitchen appliances, and accessories in India. The stock is seen making impulse waves to the upside since Jan 2023. It made the first impulse (wave 1) from Jan. - April 2023. Wave 3 seems to have started off in May 2023 and is likely getting extended. Wave I of 3 was formed between May and July 2023 and then there was a 75% retracement of wave I from July-oct. Wave III of 3 has now kicked off and volume too is picking up. The projected target for this wave should be the 850-870 zone SL 650 CMP 696 Target 860
NSE:CARYSILLong
by neeraj_2_sharma
A new 40% wave towards 900 in HDFC LIFEHDFC LIFE INSURANCE COMPANY rallied up from 457.8 to 690.85 in a wave 1 structure beginning in march 2023 ending in July.2023. However from July the stock got into a wave 2 correction and seems to have ended the very same in Oct. end. The stock ended the wave 2 correction(technically a "flat" according to Elliot wave theory) at a very crucial support/resistance zone of 600 that is relevant since May.2022. Coming to the very recent price action of the stock, the stock traded in a very narrow range for 7 days(613-626)between 1st Nov. till 9th Nov. and is now looking to break out of this range.(Generally referred to as NR7 breakout.) The 600 level has worked as a very good support for the stock and therefore SL can be placed below it at 595-597 to try and catch the new upcoming wave that can give 40% returns going forward into 2024. Note*- kindly try to understand the business model and key fundamentals of a company before making any investing decisions.
NSE:HDFCLIFELong
by neeraj_2_sharma
IHS confirmed , next BIG short squeeze?Long and strong IHS confirmation breakout and tested Fundamentals: Company fully funded and largest factory in Moses Lake has started production with recent contract signed for the next 10 years worth around 3 busd. Todays mcap is around 0.6 busd. Guided ebidta for 2025 is 100-300 musd Dept around 260 musd with favorable terms Production within 3 megatrends in the U.S, semi chips, solar and batteries (silane gas) All production sold out, but silicon anodes manufacturers ( Sila Nano, G14, Oned) has established around their Moses Lake facility in hopes for silane offtake. Amprius and Cenate has mentioned and hopes for REC silicon silane gas, and company itself says they have discussions with multiple companies regarding silane. REC has 70% markets share of silane gas, and it looks that replacing grafite with silicon will be the next big thing. The potential for REC silicon and its silane gas are endless the next 5 years as this explodes. REC also has a 15% stake in Yulin factory in China, and are in proccess of selling this stake, which is valued to 150 musd. 1/4 of todays mcap just in cash!! Proccess is going slow but we are close to an end... This stock is worth following the next year!! Also to mention is that due to restart and impairments, Moses Lake factory(replacement cost 1.7 busd) is zero in the books. Yulin has also been written down to zero... and revarsal of impairments would most likely be reversed next quarter, Yulin is a huge bonus with cash, and company has also recievd a large amount of pre payments in the 3 busd contract recently signed. Today REC silicon is one of the most shorted stocks in Oslo stock exchange, but there is a huge chance of a potential short squeeze here when market discovers fully what is about to happen here....
OSL:RECSILong
by Sirbalo
A new wave up beginning in CAT World's largest manufacturer of construction equipment - Caterpillar(CAT), is all set to make a leap upwards of 30+% in the first half of 2024. The stock of this company has been constantly making new ATH's and displays neat waves everywhere. The move being discussed and anticipated shall be 1-2-i-ii-iii, Meaning the wave iii of 3.(you can imagine it as a smaller third wave inside of a bigger third wave. The projected target zone for the anticipated wave is placed at 325-350$ zone. A look at the support/resistance zones also shows the stock attempting to reverse off a major S/R zone. The construction and manufacturing sectors have slowing started picking up and the US economy is better off than it was in 2022 and 2023. It is therefore expected of these sectors to do better in 2024 than they did in 2023 and increase their operations and output. This in turn should point towards a good business year for CAT since manufacturing, construction and mining sectors form its major customer base. Note*- This chart is based on personal observations/opinions. Please be cautious while making any financial decisions.
NYSE:CATLong
by neeraj_2_sharma
"THE DARK KNIGHT WILL RISE"_WARNER BROS to DOUBLE??The stock of the film and entertainment giant - Warner Bros set out in an impulsive Wave 1 in Dec of last year and had a 80% rally till Feb 2023. That was the end of Wave 1 for the stock and then since then the stock has only seen darkness. But darkness only makes the dark knight stronger (:P). The stock has given up on almost all the gains it made during the Wave 1 rally and has retraced 90% of it!!! With where the stock is currently placed this is a long term bet that cannot be missed/ignored because of the unmatchable risk/reward it is offering at the moment. The Wave 3 target for the stock is projected to be around 22-25$ mark. BEHOLD!! Note*- This analysis is based on personal observations/opinions. Kindly do your own research before making any financial decisions.
NASDAQ:WBDLong
by neeraj_2_sharma
1
Why Boiron Stock Deserves Attention. Stock to buyAre you a believer in the power of natural remedies and alternative medicine? If so, get ready to discover a hidden gem in healthcare stock investments – Boiron stock. Homeopathy has been gaining traction as an effective and holistic approach to healing for centuries, and now it’s time to uncover its potential from an investor’s perspective. Join me as I delve into why Boiron stock deserves your attention, unravelling the mysteries behind this ancient practice and exploring the promising future. Get ready to be captivated by the untapped opportunities waiting within this fascinating industry! The stock has reached a solid monthly demand imbalance at €39 per share. The price of this French stock has already started to rally since the imbalance took control last 23rd October 2023. Watch the video below for a complete analysis of this French stock.
EURONEXT:BOILong
by AlfonsoMoreno
Wave V of 3 in INDIGOThe airline company is seen trying to begin the wave iii of V of 3 in an attempt to go past previous ATH and then towards the 3K mark. It should also be noted that Indian airlines will operate a total of 23,732 flights every week during the winter schedule( approved by the Directorate General of Civil Aviation (DGCA). As per the new order, the said number of departures is an 8 per cent rise in the number of flights compared to a year ago period. Since indigo is the largest Indian passenger carrier it will benefit from this upbeat schedule. It presents a good trading set up with excellent RR SL- 2390 TGT- 2790
NSE:INDIGOLong
by neeraj_2_sharma
TRADE SETUP_ 10% upside for COROMANDELThis specialty chemical stock is seen in a beautiful Elliot wave structure since the Jan 2023 and has outperformed not only its peers but also major Indian Indices. The stock recently had a steep and swift decline in October. This very declined was in fact the wave iv of wave 3 and now the stock has kicked off in the Wave v of Wave 3 structure. It would be wise to wait for a small dip in the stock(towards 1070-1080) to make an entry and ride next wave up towards the 1215 zone. Note*- Please do own your own research and analysis before taking up any financial positions.
NSE:COROMANDELLong
by neeraj_2_sharma
ULTRATECH CEMENT- PATHWAY TO 12K AS PER WEEKLY WAVE COUNTSThe largest and most prosperous cement company of India- Ultratech Cement is expected to have more upside of 30-40% from current levels as the weekly wave counts suggest. To put it in very simple words without using too much of Elliot wave jargon, the next leg up is unfolding now which can be projected going somewhere closer to 9200.(the current wave structure technically should be labeled as 1-2-I-II-i-ii-iii-iv-v, which is simply read as Wave v of Wave III of Wave 3). The inner rising channel boundaries can be used as a pathway until the bigger wave 3 does not complete. I hope the chart is self explanatory and would not require too much of decoding as to what i am trying to convey. Note*- this is not a buy/sell recommendation. this post is for educational purpose only.
NSE:ULTRACEMCOLong
by neeraj_2_sharma
Good-Buy STOCKS: HOODHi Traders, Investors and Speculators of Charts📈📉 After losing nearly 90% of it's high, NASDAQ:HOOD is currently trading close to all-time lows. This could make for a great buy and hold opportunity, whilst some patience may be needed to wait for ideal target zones. Higher lows are observed after bottoming out at $6, indicating that the bottom is most likely in for HOOD. In other words a spot entry here has a really low risk and high reward setup. _______________________ 📢Follow us here on TradingView for daily updates and trade ideas on crypto , stocks and commodities 💎Hit like & Follow 👍 We thank you for your support ! CryptoCheck NASDAQ:HOOD
NASDAQ:HOODLong
by CryptoCheck-
9
SRPT Sarepta Therapeutics Potential Buyout SoonIf you haven`t bought SRPT here: Then you need to know that there is a Massive catalyst coming! Sarepta Therapeutics is going to announce Duchenne muscular dystrophy Phase 3 data for its SRP-9001-301 - (EMBARK) by mid November. This week institutions bought calls worth more than $10Mil that SRPT Sarepta Therapeutics will trade above $135 by November 17. Some even bought the $210 strike price! They also have a big partnership with the giant Roche Holding AG (RHHBY). I think SRPT Sarepta Therapeutics is well positioned for a potential takeover soon! Looking forward to read your opinion about it.
NASDAQ:SRPTLong
by TopgOptions
ACRS Aclaris Therapeutics Potential BuyoutACRS Aclaris Therapeutics has 3 clinical trials releasing topline data this year and sufficient cash to fund their operations through the end of 2025. ACRS is in Piper Sandler`s potential 12 biotech takeovers in 2023. ACRS reached 52 week low today: $5.05. Analysts Price Targets: $21 The Goldman Sachs Group $29 BTIG Research $38 Cantor Fitzgerald $43 HC Wainwright Considering the above, I think ACRS might be an easy +3X! Looking forward to read your opinion about it.
NASDAQ:ACRSLong
by TopgOptions
3
Naga Dhunseri Mid Term Idea with an RR of 1:5, 50% + ROI1) The stock is poised for a multiyear breakout, it has formed an ascending triangle pattern in monthly timeframe indicating a strong up move once after the ATH is broken. 2) Candlesticks show extremely bullish price action. Inside bars in Monthly as well. 3) RSI in monthly and weekly are supportive, moving up after a small correction. For a swing trade - One can enter at the demand 1 level if there is a reversal in hourly / 75 min time frame and look for Target 1 and Target 2 zones as targets. 10% up move. For a mid term trade - One can look to enter at the same demand zone as swing, or once after the ATH is sold off at first and then at a further upside reversal, precisely after a dip and bounce back in Daily timeframe RSI as currently it is inching 90+. As per risk management. For the Mid term, SL can be at 1500. Targets at 3100. Wish you all profits and happy trading!
NSE:NDGLLong
by Rugminik
1
NVAX Novavax Vaccine approved! Buy Opportunity!If you haven`t bought NVAX during the pandemic: Then you need to know that NVAX Novavax's recent achievements in gaining full marketing authorization for its COVID-19 vaccine, Nuvaxovid, in the UK and Singapore, alongside its availability in major U.S. pharmacies, have ignited optimism among investors. These milestones signify a bright future for NVAT stock. The international authorization of Nuvaxovid opens doors to vast markets, enhancing revenue potential and global recognition for Novavax. the EU delayed the approval, but will update its decision by the end of this month. Nuvaxovid's availability at CVS and Rite Aid in the U.S. immediately after regulatory clearance demonstrates its acceptance and accessibility. Nuvaxovid is a protein-based COVID-19 vaccine, different from the mRNA vaccines of PFE and MRNA. My price target is $10 by the end of this month. Looking forward to read your opinion about it.
NASDAQ:NVAXLong
by TopgOptions